Remove Big Data Remove Clinical Trials Remove Compliance Remove Licensing
article thumbnail

Rare diseases, repurposing and the role of AI

pharmaphorum

These might be licensed drugs that could hold potential for a patent extension, or drugs which failed efficacy trials for an intended indication. In the quest to repurpose a drug for a rare condition, there is a need to look at any and all available data.

article thumbnail

Digital biomarkers in pharma: Q&A with Medidata’s Mark Matson 

Drug Discovery World

Having these new data leads to greater understanding and enables precision medicine. . Why are digital biomarkers important in clinical trials? . Once collected, there are data analysis considerations surrounding the large amount of data and the connection to other data sources, such as EDC and eCOA data.